Prospective multicentre clinical performance evaluation of second and third generation zotarolimus-eluting stents to treat patients with bifurcated coronary lesions

Francesco Burzotta, Carlo Trani, Maria De Vita, Claudio Larosa, Azeem Latib, Cecilia Fantoni, Stefano Benedetto, Maurizio Turturo, Alessandro Manzoli

Risultato della ricerca: Contributo in rivistaArticolo in rivista

2 Citazioni (Scopus)

Abstract

Aim To assess the "real world" clinical outcome of patients with bifurcated lesions undergoing percutaneous coronary intervention with implantation of second and third generations of zotarolimus-eluting stent. Methods and Results Nine Italian centres participated in a prospective multicentre clinical project evaluating the outcome of patients receiving zotarolimus-eluting Resolute stent and Resolute Integrity stents. Patients with bifurcated lesions entered this evaluation. Clinical characteristics and angiographic and procedural details were prospectively recorded. Clinical outcome was prospectively assessed to evaluate the occurrence of major adverse cardiac events (MACE). A total of 577 patients were enrolled. The target lesion was distal left main in 11.1% and left anterior descending artery in 52.8%, and 30.3% of lesions were Medina 1,1,1. At a mean follow-up time of 27.0 ± 13.5 months, the survival free from MACE was 91.8%. Survival free from MACE was similar in patients grouped according to different bifurcated lesion complexity. On the contrary, patients receiving a single stent had better survival free from MACE as compared with those with double stent (P = 0.005). At multivariable analysis, double stenting (but not bifurcated lesion complexity) was found to be a significant predictor of MACE (hazard ratio, 2.52; 95% confidence interval, 1.28-4.94; P = 0.007). Of note, patients receiving the second stent as a bail-out had worse survival free from MACE compared with those who received it as a planned technique (P = 0.045). Conclusion The treatment of patients with bifurcated lesions with second and third generation zotarolimus-eluting stents is associated with good long-term clinical outcomes. Clinical outcome seems to be independent of lesion complexity, but may be influenced by the stenting technique (single or double stenting as well as elective or bail-out double stenting).
Lingua originaleEnglish
pagine (da-a)15-22
Numero di pagine8
RivistaCatheterization and Cardiovascular Interventions
Volume87
DOI
Stato di pubblicazionePubblicato - 2016

Keywords

  • Aged
  • Cardiology and Cardiovascular Medicine
  • Coronary Angiography
  • Coronary Artery Disease
  • Coronary Vessels
  • Drug-Eluting Stents
  • Female
  • Follow-Up Studies
  • Humans
  • Immunosuppressive Agents
  • Male
  • Percutaneous Coronary Intervention
  • Prospective Studies
  • Prosthesis Design
  • Radiology, Nuclear Medicine and Imaging
  • Resolute Integrity stent
  • Resolute stent
  • Sirolimus
  • Time Factors
  • Treatment Outcome
  • bifurcation lesions
  • provisional approach

Fingerprint Entra nei temi di ricerca di 'Prospective multicentre clinical performance evaluation of second and third generation zotarolimus-eluting stents to treat patients with bifurcated coronary lesions'. Insieme formano una fingerprint unica.

Cita questo